Obesity drug coverage shifts

CVS Caremark’s decision to stop covering Zepbound on many plans has turned obesity-drug access into an insurance fight, not just a prescribing decision. (npr.org) For patients affected by the switch, the change traces back to July 1, 2025, when CVS Caremark removed Eli Lilly’s Zepbound from key formularies and gave preferred status to Novo Nordisk’s Wegovy. Massachusetts’ Group Insurance Commission said the move was part of quarterly formulary updates aimed at managing fast-rising GLP-1 spending. (mass.gov) NPR reported that Meghan Lena, a Massachusetts special education teacher, had paid a $30 monthly copay for Zepbound and lost 50 pounds in a year before CVS Caremark told her it was being dropped. She switched to Wegovy, then lost that coverage too when her employer plan dropped Wegovy in October. (npr.org) The drug class at the center of the fight, GLP-1 medicines, helps people lose weight by mimicking gut hormones that reduce appetite and slow digestion. NPR, citing GoodRx research based on MMIT formulary data covering more than 190 million people, said 12 million people lost Zepbound coverage and another 12 million lost Wegovy coverage from 2025 to 2026. (npr.org) Among people who still had coverage for a GLP-1 drug, 88% faced at least one restriction such as prior authorization or step therapy, according to the same GoodRx analysis. That leaves formularies — the covered-drug lists set by pharmacy benefit managers and insurers — deciding which obesity drug patients can actually get. (npr.org) The federal government is now trying to keep Medicare access from breaking down in the same way. The Centers for Medicare & Medicaid Services said its Medicare GLP-1 Bridge will run from July 1, 2026, through December 31, 2027, giving eligible Medicare Part D beneficiaries access to certain GLP-1 drugs while a broader model is delayed. (cms.gov) CMS said the bridge program will operate outside the normal Medicare Part D payment flow, so Part D sponsors will not carry the financial risk and do not have to opt in for eligible patients to get the drugs. In 2026, CMS said a single central processor will handle prior authorization, claims adjudication and pharmacy payment. (cms.gov) Reuters reported that CMS delayed the Medicare Part D portion of its BALANCE model for 2027 after insurers hesitated to participate, and said the bridge will preserve access at prices negotiated with Eli Lilly and Novo Nordisk. CVS Health told Reuters it did not opt in before the April 20 deadline, while UnitedHealth cited “notable challenges and outstanding questions” about the structure. (usnews.com) CVS has said preferring Wegovy is a cost-control tool, not an effort to end coverage for obesity treatment. But patients sued the company in 2025, arguing Zepbound and Wegovy are not clinically interchangeable and that some doctors had deemed Zepbound medically necessary; CVS said the case is “without merit” and said it would defend itself. (fiercehealthcare.com) What happens next is less about whether these drugs work than about who agrees to pay for them. For patients on employer coverage and for Medicare beneficiaries waiting on the federal model, the practical question is which GLP-1 sits on the formulary when the prescription reaches the pharmacy counter. (npr.org)